



# Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities

Claudia Crimi<sup>a\*</sup>, Raffaele Campisi<sup>a</sup>, Giulia Cacopardo<sup>b</sup>, Rossella Intravaia<sup>b</sup>, Santi Nolasco<sup>b</sup>, Morena Porto<sup>b</sup>, Corrado Pelaia<sup>c</sup> and Nunzio Crimi<sup>b</sup>

## ABSTRACT

**Background:** Data on mepolizumab in patients with severe eosinophilic asthma (EA) and comorbidities are needed to assess whether randomized controlled trial results are applicable in the real world.

**Objective:** To evaluate real-life effectiveness and the presence/absence of predictors of treatment response in patients with one or more comorbidities (nasal polyps, allergic rhinitis, gastroesophageal reflux disease, nonallergic rhinitis with eosinophilia syndrome, obesity, bronchiectasis) who received mepolizumab (MEPO) for the treatment of severe EA.

**Methods:** We performed a single-center retrospective study in patients with severe asthma and presence of comorbidities treated with mepolizumab at the respiratory outpatient clinic, Policlinico-Vittorio Emanuele, Catania, Italy. Health records of 31 severe asthmatic patients were retrieved and analyzed. Asthma control test (ACT) score, blood eosinophil count, forced expiratory volume in 1 s (FEV<sub>1</sub>), FEV<sub>1</sub>% of predicted and FEV<sub>1</sub>/FVC (Forced Vital Capacity) ratio, oral corticosteroid (OCS) dosage, and exacerbations were recorded at baseline (T0), after 3 (T1), 6 (T3), 9 (T6), and 12 months (T12). Clinical response was defined when 3 of these 4 criteria were fulfilled: i) 30% exacerbation decrease; ii) 80% blood eosinophilia reduction; iii) 3 point ACT increase; iv) FEV<sub>1</sub> increase  $\geq$ 200 mL.

**Results:** 83.87% of patients were classified as responsive to MEPO treatment. Substantial depletion of the blood eosinophils (>80%) was found in 87.1% of patients, FEV<sub>1</sub> > 200 mL was seen in 54.84% of patients, a 3-point ACT improvement from baseline was recorded in 80.65% of patients and a 30% reduction of exacerbations rates was seen in 96.77% of patients. Moreover, the majority 38.71% of patients met 3/4 parameters after 12 months. Neither the comorbidities nor other characteristics (sex, BMI, age, smoking) influenced treatment response.

**Conclusions:** MEPO in patients with severe EA is effective regardless of the presence of comorbidities.

**Keywords:** Mepolizumab, Severe eosinophilic asthma, Multiple comorbidities

<sup>a</sup>Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Catania, Italy

\*Corresponding author. Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Via S. Sofia, 78, 95123, Catania, Italy. E-mail: [dott.claudiacrimi@gmail.com](mailto:dott.claudiacrimi@gmail.com)

Full list of author information is available at the end of the article

<http://doi.org/10.1016/j.waojou.2020.100462>

Received 26 February 2020; Received in revised form 27 August 2020; Accepted 31 August 2020

Online publication date xxx

1939-4551/© 2020 The Author(s). Published by Elsevier Inc. on behalf of World Allergy Organization. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## INTRODUCTION

Severe eosinophilic asthma (EA) is a subtype of asthma characterized by persistent eosinophilic airway inflammation and recurrent exacerbations despite treatment with high doses of glucocorticoids.<sup>1</sup>

In the last decade, several biological molecules with a steroid-sparing effect have been introduced in the field of severe asthma. Mepolizumab (MEPO) is an IgG1/k class humanized monoclonal antibody approved in patients  $\geq 12$  years of age for the treatment of moderate-to-severe eosinophilic asthma, owing to its ability to block circulating interleukin-5 (IL-5) responsible for eosinophil development, maturation, and survival.<sup>2</sup>

In large placebo-controlled trials, treatment with MEPO was well tolerated, resulting in a substantial fall in blood eosinophils and a significant reduction of intake/dosage of oral corticosteroids (OCS), reduction of exacerbations, and an overall improvement of lung function.<sup>3-6</sup>

In practice, MEPO was shown to change the course of severe eosinophilic asthma thanks to its ability to reduce asthma exacerbation rates and improve quality of life in these patients, as clearly outlined in a meta-analysis of 7 randomized controlled trials (RCTs).<sup>7</sup> Moreover, severe eosinophilic asthma, just like asthma, can be associated with several comorbidities (eg, nasal polyposis, gastro-esophageal reflux disease (GERD), bronchiectasis, allergic and nonallergic rhinitis, obesity) which have a consistent impact on treatment outcome, asthma symptoms, risk of exacerbations, and patient's quality of life.<sup>8-11</sup>

Recently, researchers have been trying to identify, based on the presence of comorbidities or lifestyle habits (ie, smoking), specific asthma phenotypes with the ultimate goal of personalizing the therapeutic approach. However, at present, the characteristics of these phenotypes and the impact of treatment on each of them are still not fully answered questions.<sup>12</sup>

Thus, the monitoring of new biological agent effectiveness in real-life practice may provide, in a heterogeneous disease like asthma, relevant data complementary to those of randomized control

trials.<sup>13</sup> Moreover, a detailed assessment of comorbidities in patients with severe eosinophilic asthma is important for clinical practice and, to the best of our knowledge, has not been outlined yet.

Under this perspective, we retrospectively examined a group of patients all presenting one or more comorbidity who received MEPO for the treatment of severe eosinophilic asthma in order to evaluate its real-life effectiveness, determine whether the presence of the comorbidities modifies the treatment response, and explore the presence/absence of potential predictors for treatment response.

## METHODS

### Study design and subjects

This was a single-center, retrospective study based on health records of patients who consulted a specialist from January 2018 to June 2019 at respiratory outpatient clinic, Azienda Ospedaliera Policlinico-Vittorio Emanuele di Catania. All outpatients  $\geq 12$  years of age prescribed with MEPO were included in the study. Severity at baseline was defined according to the GINA guidelines.<sup>14</sup>

All patients met the criteria for severe uncontrolled asthma according to the ATS/ERS guidelines<sup>1</sup> and received MEPO 100 mg subcutaneously every 4 weeks from T0 for at least 12 months (T12). All patients had  $>150$  eosinophils/ $\mu\text{l}$  and a history of at least 300 eosinophils/ $\mu\text{l}$  in the previous 12 months. Treatment compliance was strictly assessed at each clinical visit. Socio-demographic characteristics (age, sex, body mass index, smoking status, age at onset of asthma, sensitization to perennial aeroallergens) were included in the database as well as the presence of any comorbidities (nasal polyps, allergic rhinitis, GERD, nonallergic rhinitis with eosinophilia syndrome - NARES, obesity, bronchiectasis), which were objectively assessed according to standardized definitions and eventually confirmed by additional tests which are described in the online supplement (Supplementary 1). According to ERS/ATS guidelines, patients with other respiratory diseases that may share common clinical manifestations of severe asthma (ie,

bronchopulmonary aspergillosis, vasculitis, chronic cough) were excluded.<sup>1</sup> This study used anonymous retrospective claims data; as such, it did not require institutional review board review and approval or informed consent. Moreover, as it refers to outpatients treated with drugs already approved by regulatory agencies, it does not need approval by the Ethics Committee.

## Measurements

The health records for each patient were recorded at baseline (T0), after 3 (T1), 6 (T3), 9 (T6), and 12 months (T12) of treatment with MEPO. The following parameters were assessed: asthma control test (ACT) score,<sup>15</sup> blood eosinophil count, forced expiratory volume in 1 s (FEV<sub>1</sub>), FEV<sub>1</sub>% of predicted, and FEV<sub>1</sub>/FVC (forced vital capacity) ratio. Spirometry was performed according to the ATS/ERS guidelines.<sup>16</sup> FEV<sub>1</sub> and FVC were measured using a spirometer (Sensormedics, Milan, Italy). The best value of 3 consecutive maneuvers was expressed as the percentage of the normal value. After the baseline assessment, spirometry was repeated 15 min after administration of salbutamol (400 µg). Reversibility of airway obstruction was expressed in terms of percentage change from baseline FEV<sub>1</sub>. Monthly intake (mg) of prednisone and exacerbations (per period of time, corrected per year and calculated as episodes requiring systemic corticosteroid treatment for at least 3 days, and/or emergency visit or hospitalization for acute asthma) were also included in the database for all time points.

## Evaluation of the response to mepolizumab

We selected 5 parameters which are crucial in the treatment of severe eosinophilic asthma, and accordingly, patients were divided into 2 groups: responders and non-responders.

Clinical relevant response was defined as: i) a 30% decrease in the exacerbations rate;<sup>17</sup> ii) an improvement in pulmonary function (FEV<sub>1</sub> ≥ 200 mL) by analogy to the cut-offs used by the Global Lung Initiative;<sup>14</sup> iii) an 80% reduction of eosinophils in peripheral blood from baseline by analogy to the approval studies of mepolizumab,<sup>3-6</sup> and iv) a change in ACT from baseline, whereby minimal clinically relevant

difference was defined as an ACT score of 3 points.<sup>18</sup>

We did not include OCS reduction as a clinical response parameter, as not every single patient was on continuous OCS at T0. Fulfilling at least 3 of the 4 components of the primary outcome was considered a treatment success.

## Statistical analysis

Statistical analysis was performed using GraphPad Prism v8.0 (Graphpad Software, Inc., La Jolla, CA). Categorical variables are stated as numbers (n) and percentages (%).

Results are reported as mean ± standard deviation (SD) if normally distributed and median and interquartile range (IQR) if non-normally distributed unless indicated otherwise. Comparisons were performed using Chi-squared or Fisher's exact test for categorical data and Student's t-test or Wilcoxon matched-pairs signed-rank test or Mann-Whitney-U-test for continuous data.

The normality of data distribution was checked using the Shapiro-Wilk test. A logistic regression model was created to determine the effects of comorbidities, eosinophil count, body mass index, smoking, age, and gender on the outcomes. A p-value <0.05 was considered as statistically significant.

## RESULTS

### Assessment of all patients

We analyzed the data from 31 patients (mean age 52.35 years; 58% females) with severe eosinophilic asthma and on treatment with MEPO. Patients' socio-demographic characteristics, including smoking status and comorbid conditions, are displayed in Table 1. The pre-treatment IgE value of all patients involved in the study was 181 UI/mL (interquartile from 88 UI/mL to 355 UI/mL) (data not shown).

The variables at baseline and 12 months (T12) are shown in Table 2. The overall median blood eosinophil count decreased from 791 cells/ul (IQR 420–1300) at baseline to 80 cells/ul (IQR 43–109) at T12 (p > 0.0001). As shown in Fig. 1A, the median decrease was already significant

Characteristic	All (n = 31)
Age (years), mean (SD)	52.35 (9.714)
Female sex, n (%)	18 (58)
Male sex, n (%)	13 (42)
Body Mass Index, mean (SD)	26.68 (5.237)
Diagnosis of asthma, years, median (IQR)	15 (10-23)
Blood eosinophils, mean (range) median (SEM)	1219 (293-7180) 791 (273.8)
FEV <sub>1</sub> (l), mean (SD)	2.15 (0.81)
OCS therapy dependent, n (%)	21 (67.7)
OCS mg/30days, median (IQR)	56.25 (0 -112-.5)
Number of exacerbations/year, median (IQR)	6 (4-12)
<b>Smoking status, n (%)</b>	
Active smoker	3 (10)
Ex-smoker	7 (22)
Non-smoker	21 (68)
<b>Comorbid conditions prevalence, n (%)</b>	
Nasal polyps	24 (77.4)
GERD	10 (32.2)
NARES	12 (38.7)
Obesity	11 (35.5)
Allergy	22 (71)
Bronchiectasis	17 (54.8)


**Table 1.** Demographic and baseline characteristics. SD, standard deviation; IQR, interquartile range; SEM, standard error mean; GERD, Gastroesophageal reflux disease; NARES, Nonallergic rhinitis with eosinophilia syndrome

( $p < 0.0001$ ) at the first time point (T1, 3 months) and was sustained at each consecutive time point.

A significant change in mean predicted FEV<sub>1</sub> and FEV<sub>1</sub>% compared to baseline was observed at T12 ( $2.12 \pm 0.75$  versus  $2.33 \pm 0.7$ ;  $p = 0.0224$ ) and ( $73.68 \pm 21.43$  versus  $82.94 \pm 21$ ;  $p = 0.0069$ ), respectively. As shown in Fig. 1B, mean FEV<sub>1</sub> increase was already significant ( $p = 0.0455$ ) at T1 and was sustained at each consecutive time point. FEV<sub>1</sub>/FVC was significantly different from baseline only at T1 ( $79.19 \pm 16.38$ ;  $p = 0.0036$ ) and at T3 ( $82.71 \pm 16.24$ ;  $p = 0.0001$ ), but not at T6 and T12 (data not shown).

There was a significant improvement in ACT after treatment with MEPO, with a mean of  $13.65 \pm 4.54$  points at baseline and  $21.29 \pm 4.49$  points at T12 ( $p > 0.0001$ ). As shown in Fig. 1C, also for this outcome, the mean increase was already significant ( $p = 0.0455$ ) at T1 and was sustained at each consecutive time point.

At baseline, 67.7% of patients were on continuous OCS therapy with a median 30-days dose of 59.25 mg (IQR 0-112.5) of prednisone. Both OCS rates and dosage were significantly reduced at T12. Only 16.1% were still on OCS ( $p < 0.0001$ ),



**Fig. 1** Comparison of clinical parameters from baseline (T0) to 12 months (T12). (A) Median blood eosinophil count; (B) Mean of FEV<sub>1</sub>; (C) Mean of ACT score; (D) Median of OCS mg/30days. \*indicates  $p < 0.05$ . EOS, Eosinophil count; FEV<sub>1</sub>, forced expiratory volume in 1 s; ACT, asthma control test; OCS, oral corticosteroids

	Before treatment	After treatment	<i>p</i> value
FEV <sub>1</sub> % of predicted, mean (SD)	73.68 (21.43)	82.94 (21)	0.0069
FEV <sub>1</sub> (L), mean (SD)	2.11 (0.748)	2.33 (0.70)	0.0224
FEV1/FVC, mean (SD)	69.48 (15.52)	69.31 (11.23)	Ns
ACT, mean (SD)	13.65 (4.54)	21.29 (4.49)	<0.0001
Blood eosinophils, median (IQR)	791 (420–1300)	80 (43–109)	<0.0001
OCS therapy dependent, n (%)	21 (67.7)	5 (16.1)	<0.0001
OCS mg/30days, median (IQR)	56.25 (0–112.5)	0 (0–0)	0.0012
Number of exacerbations/year, median (IQR)	6 (4–12)	0 (0–1)	<0.0001

**Table 2.** Summary of effectiveness outcomes. *SD*, standard deviation; *IQR*, interquartile range; *OCS*, oral corticosteroid; *FEV<sub>1</sub>*, forced expiratory volume in 1 s; *FVC*, forced vital capacity; *ACT*, asthma control test

	Baseline			$\Delta T12-T0$		
<b>Nasal polyps</b>						
	Without (7)	With (24)	<i>p value</i>	Without (7)	With (24)	<i>p value</i>
FEV <sub>1</sub> (L)	2.024 (1.002)	2.146 (0.68)	0.712	0.284 (0.52)	0.15 (0.508)	0.7208
ACT	15.57 (5.028)	13.08 (4.343)	0.266	5.286 (6.157)	8.333 (4.556)	0.2585
OCS mg/30days	112.5 (0-112.5)	16.88 (0-112.5)	0.51	-112.5 (-112.5-0)	-11.25 (-11.25-0)	0.6997
Exacerbations/year	12 (4-12)	6 (3.25-12)	0.312	-11 (-12--4)	-6 (-12--2.25)	0.284
Eosinophils	1200 (500-1400)	711 (400-1063)	0.245	-995 (-1200--500)	-640 (-927 to -347)	0.0395
<b>GERD</b>						
	Without (21)	With (10)	<i>p value</i>	Without (21)	With (10)	<i>p value</i>
FEV <sub>1</sub> (L)	2.033 (0.782)	2.398 (0.871)	0.366	0.259 (0.424)	0.02 (0.64)	0.302
ACT	12.52 (5.47)	16 (4.807)	0.044	8.048 (5.47)	6.8 (4.022)	0.482
OCS mg/30days	56.25 (0-112.5)	67.5 (0-112.5)	0.95	-33.75 (-112.5-0)	-56.25 (-112.5-0)	0.835
Exacerbations/year	8 (4-12)	6 (2.75-12)	0.471	-7 (-12--4)	-5.5 (-12--2)	0.665
Eosinophils	800 (460-1135)	755.5 (400-1764)	0.811	-700 (-987.5--420)	-515.5 (-1569--386.8)	0.811
<b>Obesity</b>						
	Without (20)	With (11)	<i>p value</i>	Without (20)	With (11)	<i>p value</i>
FEV <sub>1</sub> (L)	2.295 (0.950)	1.868 (0.515)	0.134	0.142 (0.355)	0.09 (0.59)	0.791
ACT	14.85 (4.082)	12.09 (5.224)	0.148	7.25 (4.529)	8 (6.017)	0.7
OCS mg/30days	112.5 (2.813-112.5)	22.5 (0-98.44)	0.065	-112.5 (-112.5 - 2.813)	-21.5 (-111.5-0)	0.061
Exacerbations/year	6 (4-12)	8 (4-12)	0.961	-6 (-12--4)	-7 (-12--3)	0.88
Eosinophils	711 (405-1200)	1040 (550-1418)	0.42	-653.5 (-960.8--400)	-743 (-1110--368.0)	0.8

Bronchiectasis						
	Without (14)	With (17)	<i>p</i> value	Without (14)	With (17)	<i>p</i> value
FEV <sub>1</sub> (L)	2.133 (0.793)	2165 (0.858)	0.925	0.173 (0.49)	0.189 (0.534)	0.932
ACT	13.5 (4.926)	13.76 (4.352)	0.877	6.643 (5.583)	8.471 (4.501)	0.332
OCS mg/30days	22.5 (0-112.5)	112.5 (0-112.5)	0.334	-11.25 (-112.5-0)	-112.5 (-112.5-0)	0.313
Exacerbations/year	4 (2.75-12)	12 (5-12)	0.082	-4 (-9--2)	-11 (-12--5)	0.066
Eosinophils	970 (437.5-1449)	720 (410-985)	0.32	-685 (-1248--358.5)	-657 (-919--370)	0.604
NARES						
	Without (19)	With (12)	<i>p</i> value	Without (19)	With (12)	<i>p</i> value
FEV <sub>1</sub> (L)	2.144 (0.7882)	2.078 (0.712)	0.984	0.127 (0.469)	0.269 (0.570)	0.479
ACT	13.79 (4.709)	13.42 (4.461)	0.826	7.526 (5.621)	7.833 (4.108)	0.862
OCS mg/30days	56.25 (0-112.5)	22.5 (0-112.5)	0.553	-56.25 (-112.5-0)	-22.5 (-112.5-0)	0.742
Exacerbations/year	8 (4-12)	6 (3.25-12)	0.56	-7 (-12--4)	-6 (-11.75--2.5)	0.719
Eosinophils	898 (500-1400)	691 (400-1235)	0.482	-700 (-1110--368.0)	-653.5 (-983.8--345.8)	0.726
Allergy						
	Without (9)	With (22)	<i>p</i> value	Without (9)	With (22)	<i>p</i> value
FEV <sub>1</sub> (L)	2.421 (0.675)	1.995 (0.7558)	0.142	0.136 (0.571)	0.2 (0.49)	0.772
ACT	14 (4.5)	13.5 (4.657)	0.784	4.778 (4.764)	8.818 (4.727)	0.048
OCS mg/30days	56.25 (0-112.5)	-39.38 (-112.5-0)	0.977	-33.75 (-112.5-0)	-39.38 (-112.5-0)	0.681
Exacerbations/year	12 (2.5-12)	6 (4-12)	0.741	-8 (-11.5--1.5)	-6 (-12--4)	0.640
Eosinophils	702 (410-1364)	795.5 (437.5-1225)	0.888	-500 (-979-5 to -333.5)	-721.5 (-1024--398.3)	0.384

**Table 3.** Clinical parameters by comorbidities at baseline and at  $\Delta T12-T0$ . ACT values are expressed as mean (SD), OCS mg/30days as median (IQR), Number of exacerbations/year as median (IQR), Eosinophils as median (IQR), FEV<sub>1</sub> as mean (SD). SD, standard deviation; IQR, interquartile range; OCS, oral corticosteroid; FEV<sub>1</sub>, forced expiratory volume in 1 s; FVC, forced vital capacity; ACT, asthma control test; ns, not significant



with a lower median 30-day dose of 0 mg (IQR 0-0).

After 1 year of MEPO treatment, we observed a significant difference in the number of exacerbations/year (6, IQR 4-12 vs. 0, IQR 0-1;  $p < 0.00001$ ). All patients except one (96.77%) reduced their number of exacerbations by at least 70%. In particular, of the 17 patients (54.93%) who had more than 5 exacerbations in the year before therapy, 100% had no exacerbations at T12.

Finally, no adverse effects were observed in our cohort.

### Assessment of patients based on comorbidities

All patients had at least 1 comorbidity with a median (IQR) number of comorbidities of 3.<sup>2-4</sup>

In order to evaluate the potential impact of comorbidities on treatment effect, a comparison of blood eosinophils count, ACT score, FEV<sub>1</sub> values, and OCS median dose among the 6 groups of patients with/without nasal polyps, GERD, NARES, obesity, bronchiectasis, and allergy was performed. Table 3 shows that there was no significant difference at baseline between groups with/without comorbidities, with the only exception of ACT score between patients without and with

GERD ( $12.52 \pm 5.47$  versus  $16 \pm 4.807$ , respectively;  $p = 0.0443$ ).

We did not find any significant difference for  $\Delta T12-T0$  in any of the analyzed clinical parameters among patients with and without comorbidities, with the only exceptions of patients without nasal polyps, who showed a greater blood eosinophil reduction than those with nasal polyps ( $-995$ , IQR  $-1200$  to  $-500$  vs.  $-640$ , IQR  $-927$  to  $-347$ ;  $p = 0.0395$ ), and patients with allergy, who showed a greater ACT score than those without allergy ( $8.818 \pm 4.727$  vs  $4.778 \pm 4.764$ ;  $p = 0.048$ ) (Table 3).

The association between the median number of observed comorbidities and the  $\Delta T12-T0$  of ACT mean scores (1-2 comorbidities:  $4.625 \pm 5.878$ ; 3 comorbidities:  $8.615 \pm 5.06$ ;  $\geq 4$  comorbidities:  $8.8 \pm 3.46$ ;  $p = 0.1412$ ), of FEV<sub>1</sub> mean values (1-2 comorbidities:  $0.22 \pm 0.304$ , 3 comorbidities:  $0.1662 \pm 0.537$ ,  $\geq 4$  comorbidities:  $0.173 \pm 0.628$ ;  $p = 0.9719$ ), OCS median dose (1-2 comorbidities: 112.5, IQR -140.6 to  $-19.69$ , 3 comorbidities: 112.5, IQR  $-112.5$  to  $-90$ ,  $\geq 4$  comorbidities: 84.38, IQR  $-112.5$  to  $-30.94$ ;  $p = 0.7741$ ) and median blood eosinophilia (1-2 comorbidities: 645.5, IQR  $-109.5$  to  $-380$ , 3 comorbidities: 657, IQR  $-1087$  to  $-380$ ,  $\geq 4$  comorbidities: 696.5,

	N	%
Overall response	26	83.87
Outcome summary (number of fulfilled parameters)		
4/4	12	38.71
3/4	14	45.16
2/4	4	12.9
1/4	1	3.22
0/4	0	0
With Nasal polyps	21	87.5
With GERD	8	72.72
With NARES	9	75
With Obesity	9	87.5
With Allergy	18	81.82
With Bronchiectasis	14	82.35

**Table 4.** Response to treatment with mepolizumab. GERD, Gastro-esophageal reflux disease; NARES, Nonallergic rhinitis with eosinophilia syndrome



IQR -1013 to -375;  $p = 0.9933$ ) was not significant.

### Clinical response

According to our clinical response parameters, 83.87%<sup>26</sup> of patients were classified as responsive to MEPO treatment. A substantial depletion of the blood eosinophils (less than 80% from baseline) was found in 87.1% of patients, improvement in lung function ( $FEV_1 > 200$  mL) was seen in 17 patients (54.84%), 3-point improvement in ACT from baseline was recorded in 25 patients (80.65%) and a 30% reduction of exacerbations rates was seen in 30 patients (96.77%).

Moreover, the majority of patients (38.71%) met 3/4 parameters after 12 months, as shown in Table 4 (Table 4).

The characteristics of the 5 non-responding patients are summarized in Table 5.

### Predictive factors

In order to identify potential predictive factors of MEPO response, we analyzed if every single comorbidity, and smoking status, gender (female), age  $\geq 65$  years-old, BMI  $\geq 25$  kg/m<sup>2</sup>, and blood eosinophil count  $\geq 500$ /mm<sup>3</sup> of these 31 patients were associated with allocation to a specific treatment response group (responders or non-responders). As shown in Fig. 2, each of the

analyzed variables achieved a significant value of  $p > 0.05$  in the univariate model; thus, none of them influenced allocation to a specific treatment response group.

### DISCUSSION

Our study assessed not only the efficacy of mepolizumab in patients with severe eosinophilic asthma complicated by the presence of one or more comorbidities but also whether these affected the treatment outcome or not.

Our first analysis led us to conclude that the treatment with mepolizumab for one year substantially improved all the analyzed clinical parameters. Mepolizumab resulted in a significant reduction in asthma exacerbations, use and dose of OCS, blood eosinophilia and a concomitant improvement in pulmonary function and asthma symptoms control in all patients.

The overall response rate was of 83.87%. In particular, blood eosinophil count decreased by 89.89%, a 3-point improvement in ACT from baseline was recorded in 80.65% of patients and exacerbations rates were virtually zeroed, as 96.77% of patients had a reduction in the number of exacerbations by minimum 30% and at least 70% during the year of treatment with mepolizumab.

Also, a sharp reduction in the use of OCS was recorded in our cohort, as 84% of patients discontinued the OCS at follow-up, a percentage higher than so far reported in other studies.<sup>19-23</sup>

In our cohort,  $FEV_1$  values increased only by 9% and the  $FEV_1/FVC$  difference between follow-up and baseline was statistically significant at 3 months but not at 12 months; these data seem to align with those of other studies.<sup>21</sup> The  $FEV_1/FVC$  result could be explained as a concomitant increase of airway caliber and reduction in the residual volume (RV), which usually takes place in response to asthma treatment and improves both  $FEV_1$  and FVC.<sup>24</sup>

Overall, our results are comparable with those attained in both randomized and real-life analyses.<sup>3-6,20-23,25,26</sup>

Also, it is important to underline that our data not only confirm the efficacy of MEPO but also highlight the rapidity of the therapeutic effect. In




Fig. 2 Analysis of potential predictors of treatment outcome. EOS, eosinophil count; BMI, body mass index; GERD, Gastroesophageal reflux disease; NARES, Nonallergic rhinitis with eosinophilia syndrome

Patient	Age	Comorbidity	Missed Outcome
A	70	Bronchiectasie	FEV <sub>1</sub> ↑, ACT↑
B	46	Nasal polyps, GERD, Obesity	FEV <sub>1</sub> ↑, ACT↑, Blood eosinophils↓
C	69	GERD, NARES, Allergy	FEV <sub>1</sub> ↑, ACT↑
D	55	Nasal polyps, NARES, Allergy, Bronchiectasie	FEV <sub>1</sub> ↑, ACT↑
E	41	Nasal polyps, GERD, NARES, Allergy	FEV <sub>1</sub> ↑, Blood eosinophils↓

**Table 5.** Characteristics of non-responder patients. GERD, Gastro-esophageal reflux disease; NARES, Nonallergic rhinitis with eosinophilia syndrome; FEV<sub>1</sub>, forced expiratory volume in 1 s; ACT, asthma control test

our study, a significant improvement in FEV<sub>1</sub> and blood eosinophil count was already evident after 3 months and was sustained for 12 months. The quick beneficial effect of MEPO was in accordance with the reported patient's ACT score, which also significantly improved within the first 3 months. An equally rapid response, even within the first month of treatment, has been highlighted in other real-life studies.<sup>19,20,22,23,25</sup>

In our cohort, only 5 patients did not exhibit, according to our criteria, an effective response to treatment. These patients had an average age of 56.2 years old (minimum 50, maximum 70) and had distinctive comorbidities or combinations of comorbidities without a recurrent pattern. The outcome that was mostly not achieved among these 5 patients was the increase of 200 mL in FEV<sub>1</sub>, followed by the 3-point increase in the ACT score, and in only 2 patients the 80% decrease in the level of eosinophils in the blood. However, our clinical response cut-off was particularly stringent and, in general, the clinical conditions of these patients were ameliorated by MEPO therapy.

Our second analysis questioned whether patients with specific comorbidities achieved different results in treatment outcomes. Among patients with or without a comorbidity, we did not find any statistically significant difference. The only exceptions were patients without nasal polyps, who showed a more significant reduction in blood eosinophilia than patients with nasal polyps ( $p = 0.0395$ ), and patients with allergy, who showed a more considerable improvement in their ACT score than those without allergy ( $p = 0.048$ ).

Not even the number of comorbidities influenced treatment with MEPO, as no difference in achieving the therapeutic success was found

among patients having 1–2 comorbidities, 3 comorbidities or more than 4 comorbidities.

These data are particularly useful to assess the role of mepolizumab better as we provide an insight into real-life characteristics of all eligible patients. Our 31 patients had a median number of 3 comorbidities, a situation that differed largely from that of RCTs, in which patients do not present any concomitant disease. In this regard, a recent real-life study by Bagnasco and colleagues compared the characteristics at baseline of its cohort with those of patients enrolled in MEPO RCTs.<sup>27</sup> Their results underline how real-life patients were characterized by a greater age, a worse lung function, a higher level of eosinophilia, and a higher dosage of OCS compared to RCT patients.<sup>27</sup>

If we compare the baseline characteristics of our cohort with the cohort of the study of Bagnasco and colleagues, it is possible to observe an even higher level of eosinophilia at baseline ( $653 \pm 381$  vs.  $1219 \pm 1585$  respectively;  $p = 0.0034$ ), a similar baseline level of FEV<sub>1</sub>%, and a greater annual recurrence of exacerbations ( $3 \pm 1.8$  vs.  $7.58 \pm 4.178$ ;  $p < 0.0001$ ).

Taken together, these data suggest that mepolizumab is capable of exerting its beneficial action in patients with severe eosinophilic asthma despite the presence of one or more comorbidities.

To date, only 2 studies have assessed the effectiveness of MEPO in patients with comorbidities, and both corroborate our data.<sup>28,29</sup> The first study has evaluated MEPO outcomes after 12 months of treatment in 4 severe uncontrolled asthmatic patients with bronchiectasis.<sup>28</sup> Results revealed a significant increment in ACT and lung

function, a reduction in the number of exacerbations/year, and a reduction of blood eosinophilia.<sup>28</sup> The second study has found a correlation between the presence of eosinophilic chronic rhinosinusitis (ECRS) and therapeutic response in patients with severe eosinophilic asthma.<sup>29</sup> In particular, Numata and colleagues identified in 28 patients that ECRS was a predictive factor of the response to mepolizumab as patients with eosinophilic chronic rhinosinusitis showed significantly improved systemic corticosteroid-sparing effects, lung function and symptoms compared to patients without the comorbidity.<sup>29</sup>

In order to extend our analysis, we probed if single comorbidities influenced allocation to the responder or non-responder group. Neither the comorbidities nor other characteristics of patients at baseline (ie, sex, BMI, age, smoking habits, baseline eosinophil count) affected the success or failure of MEPO therapy. Other studies evaluated some socio-demographic factors (ie, allergy, BMI, eosinophils, and lung function at baseline, age, sex, and smoking habits) and 2 of them identified potential predictive factors of MEPO response.<sup>25,30,31</sup> A supervised cluster analysis with a recursive partitioning approach applied to the Dose Ranging Efficacy And safety with Mepolizumab (DREAM) data identified BMI as a predictor.<sup>30</sup> However, the data on this topic are rather controversial, and there is no general agreement as to the role of BMI as a predictive factor of outcome.<sup>25,30</sup>

Finally, like other real-life studies, our data do not indicate the number of eosinophils as a predictor of clinical efficacy, suggested by some other authors as a useful biomarker for the selection of patients who are more likely to benefit from treatment with MEPO.<sup>21,25,30,32-34</sup>

There are several limitations to the present study. One limitation is that it is a single-center, retrospective study. However, the alignment of our results with those from the literature makes the data more robust. Secondly, the conclusions about predictive factors could be limited due to the small number of patients included in the study. Thirdly, no established criteria for treatment response have been validated yet; therefore, our criteria could be classified as subjective. Finally, we acknowledge

that the small sample size, the retrospective design, and methods of the study might limit addressing whether comorbidities modify the treatment effect of mepolizumab on asthma outcomes.

## CONCLUSIONS

Asthma is a heterogeneous disease with different clinical manifestations; therefore, the systematic investigation of flawless biomarkers or composite indexes which could help clinicians identify patients predisposed to specific therapeutic strategies is still an unmet need.

These findings, while preliminary, suggest that treatment with MEPO is effective in clinical practice in patients with severe eosinophilic asthma complicated by 1 or more comorbidities. However, as we were not able to establish a predictive outcome factor, further larger studies, which take these variables into account, will need to be undertaken.

### Abbreviations

ACT: Asthma Control Test; BMI: Body Mass Index; DREAM: Dose Ranging Efficacy And safety with Mepolizumab; EA: Eosinophilic Asthma; ERS/ATS: European Respiratory Society/American Thoracic Society; ECRS: Eosinophilic Chronic Rhinosinusitis; FEV1: Forced Expiratory Volume in 1 s; FVC: Forced Vital Capacity; FEV<sub>1</sub>/FVC: Forced Expiratory Volume in 1 s/Forced Vital Capacity ratio; GERD: Gastro-Esophageal Reflux Disease; GINA: Global INitiative for Asthma; IgG: Immunoglobulin G; IL-5: Interleukin-5; IQR: Interquartile Range; MEPO: Mepolizumab; NARES: Non Allergic Rhinitis with Eosinophilia Syndrome; OCS: Oral Corticosteroid; RCTs: Randomized Controlled Trials; RV: Residual Volume; SD: Standard Deviation; SEM: Standard Error Mean; T0: baseline; T1: 3 months after baseline; T3: 6 months after baseline; T6: 9 months after baseline; T12: 12 months after baseline

### Funding

Not applicable.

### Ethical approval

This study used anonymous retrospective claims data, and as such, it did not require institutional review board and approval or informed consent. Moreover, as it refers to outpatients treated with drugs already approved by regulatory agencies, does not need approval by an Ethics Committee.

### Submission declaration

The work has not been published or submitted to another scientific journal and is not being considered for publication elsewhere, though it was uploaded to a preprint server in an earlier version (<https://www.medrxiv.org/content/10.1101/2020.05.26.20112052v1>). This submission represents original work and is approved by all authors.

### Consent for publication

All authors approved publication of the work.

### Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Authors' contributions

NC, CC and RC designed the study. GC, SN, RI, MP, CP, contributed to the clinical and laboratory work for the study. GC, SN, RI and MP contributed to data collection. CC contributed to data analysis. RC, CC, and NC drafted the article and revised it critically for important intellectual content. RC, CC, and NC contributed to final approval of the version to be published. All authors contributed to drafting, revising and editing the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

### Declaration of competing interest

All the authors declare no competing interests.

### Acknowledgements

Editorial assistance for the manuscript was provided by scienced medical communication.

### Appendix A Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.waojou.2020.100462>.

### Author details

<sup>a</sup>Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Catania, Italy. <sup>b</sup>Respiratory Medicine Unit, A.O.U. "Policlinico-Vittorio Emanuele", Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. <sup>c</sup>Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy.

## REFERENCES

1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43(2):343-373.
2. European Medicine Agency (Ema). [https://www.ema.europa.eu/en/documents/overview/nucala-epar-medicine-overview\\_en.pdf](https://www.ema.europa.eu/en/documents/overview/nucala-epar-medicine-overview_en.pdf) Last accessed 25 november 2019.
3. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med*. 2017;5(5):390-400.
4. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*. 2012;380(9842):651-659.
5. Ortega HG, Liu MC, Pavord ID, et al. MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*. 2014;371(13):1198-1207.
6. Bel EH, Wenzel SE, Thompson PJ, et al. SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014;371(13):1189-1197.
7. Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. *PLoS One*. 2013;8(6).
8. Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'. *J Intern Med*. 2012;272(2):133-143.
9. Scott HA, Gibson PG, Garg ML, et al. Relationship between body composition, inflammation and lung function in overweight and obese asthma. *Respir Res*. 2012;13(1):10.
10. Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison? *Curr Opin Allergy Clin Immunol*. 2019;19(1):46-52.
11. Boulet LP, Boulay MÈ. Asthma-related comorbidities. *Expert Rev Respir Med*. 2011;5(3):377-393.
12. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med*. 2012;18(5):716-725.
13. Saturni S, Bellini F, Braido F, et al. Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. *Pulm Pharmacol Therapeut*. 2014;27(2):129-138.
14. InitiativeforAsthma G. *Global Strategy for Asthma Management and Prevention*; 2016. Available at: [www.ginasthma.org](http://www.ginasthma.org).
15. Korn S, Both J, Jung M, et al. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. *Ann Allergy Asthma Immunol*. 2011;107(6):474-479.
16. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS task force. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319-338.
17. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. *Lancet Respir Med*. 2016;4(7):549-556.
18. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. *J Allergy Clin Immunol*. 2009;124(4):719-723.e1.
19. Pelaia C, Busceti MT, Solinas S, et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. *Pulm Pharmacol Therapeut*. 2018;53:1-5.

20. Pertzov B, Unterman A, Shtraichman O, et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. *J Asthma*. 2019;1-6.
21. Bagnasco D, Caminati M, Menzella F, et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. *Pulm Pharmacol Therapeut*. 2019;58:101836.
22. Caminati M, Cegolon L, Vianello A, et al. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. *Expet Rev Respir Med*. 2019;13(12):1205-1212.
23. Montero-Pérez O, Contreras-Rey MB, Sánchez-Gómez E. Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice. *Drugs Context*. 2019;8:212584.
24. Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. *J Allergy Clin Immunol*. 2012;129(3 Suppl):S65-S87.
25. Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. *BMC Pulm Med*. 2018;18(1): 119.
26. Quanjer PH, Stanojevic S, Cole TJ, et al, ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40(6):1324-1343.
27. Bagnasco D, Milanese M, Rolla G, et al. The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials. *World Allergy Organ J*. 2018;11(1):34.
28. Carpagnano GE, Scioscia G, Lacedonia D, et al. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. *J Asthma Allergy*. 2019;12:83-90.
29. Numata T, Nakayama K, Utsumi H, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. *BMC Pulm Med*. 2019;19(1):176.
30. Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. *Ann Am Thorac Soc*. 2014;11(7):1011-1017.
31. Albers FC, Papi A, Taillé C, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. *Respir Res*. 2019;20(1):169.
32. Albers FC, Licskai C, Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. *Respir Med*. 2019;159:105806.
33. Walsh GM. Severe eosinophilic asthma and mepolizumab. *Lancet Respir Med*. 2016;4(7):528-529.
34. Pelaia C, Crimi C, Pelaia G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. *Clin Exp Allergy*. 2020;50(7):780-788.